cross-listing

Onco‑Innovations announced it has hired a U.S. investment bank to advise on a possible Nasdaq cross‑listing and assess a concurrent equity financing. The advisory will evaluate listing requirements, regulatory and governance issues, and capital‑raising strategies. While the engagement signals interest in U.S. market access and additional capital, the company cautions that neither a listing nor financing is guaranteed and details remain under discussion.